Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

181. Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation (Abstract)

Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation It is unclear how polyethylene glycol (PEG) laxatives compare with other classes of laxative in terms of efficacy. To assess efficacy of PEG vs. placebo and active comparators in adults with non-organic constipation. Text Word searches were carried out on MEDLINE, EMBASE, CINAHL, Cochrane Central Register of Clinical Trials and Google Scholar databases covering the period January 1970 to October (...) 2009. Search terms were (constipation) AND (randomised OR randomized) AND (PEG OR polyethylene OR macrogol OR movicol OR idrolax OR miralax OR transipeg OR forlax OR colyte OR golytely OR isocolan OR nulytely) NOT colonoscopy. Only published randomised controlled trials, with a parallel-group or cross-over design, comparing oral PEG with placebo or a comparator laxative in adults with a history of non-organic constipation, were included. The frequency of defaecation in each arm, on completion

2010 EvidenceUpdates

182. Digital rectal exams in children who present with constipation

Digital rectal exams in children who present with constipation BestBets: Digital rectal exams in children who present with constipation Digital rectal exams in children who present with constipation Report By: Nesba Naheed - Medical Student Search checked by Rachel Jenner - Consultant in Emergency Medicine Institution: Manchester Royal Infirmary Date Submitted: 5th June 2007 Date Completed: 8th June 2010 Last Modified: 8th June 2010 Status: Green (complete) Three Part Question In a [child (...) presenting with constipation] is a [digital rectal examination] recommended to [confirm the diagnosis]? Clinical Scenario A five year boy is presented to the Emergency department by his mother. His mother complains that he has constipation. After examining the boy's abdomen you wonder whether in order to confirm the diagnosis you should perform a digital rectal exam (DRE). Search Strategy Medline using the OVID interface 1950 to January Week 2 2010: (constipation.mp OR exp Constipation/ exp Feces/ or exp

2010 BestBETS

183. The use of senna with docusate for postoperative constipation after pelvic reconstructive surgery: a randomized, double-blind, placebo-controlled trial (Abstract)

The use of senna with docusate for postoperative constipation after pelvic reconstructive surgery: a randomized, double-blind, placebo-controlled trial The objective of the study was to compare time to first bowel movement (BM) after surgery in subjects randomized to placebo or senna with docusate.Ninety-six subjects completed a baseline 7-day bowel diary before and after surgery. After pelvic reconstructive surgery, the subjects were randomized to either placebo (n=45) or senna (8.6 mg

2010 EvidenceUpdates Controlled trial quality: predicted high

184. Management of constipation.

Management of constipation. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline Clearinghouse (NGC) has ended

2010 University of Iowa Gerontological Nursing Interventions Research Center, Research Translation and Di

185. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation (Abstract)

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation Although it has been used as a laxative for many years, high-quality trials assessing the efficacy of the laxative sodium picosulfate (SPS) are lacking. The purpose of this study was to assess the efficacy and safety of 4-week treatment with SPS in patients with functional constipation as defined by the Rome III diagnostic criteria.This study was a randomized (...) , double-blind, placebo-controlled, parallel-group study in 45 general practices in Germany. A total of 468 patients with chronic constipation presenting to their general practitioner and fulfilling the Rome III diagnostic criteria were screened. After a 2-week baseline period, 367 patients were randomized to either SPS drops or matching placebo in a 2:1 ratio for 4 weeks. Dose titration was permitted throughout treatment. Patients without a bowel movement for more than 72 h were allowed to use

2010 EvidenceUpdates Controlled trial quality: predicted high

186. Constipation: A Global Perspective

Constipation: A Global Perspective © World Gastroenterology Organisation, 2010 World Gastroenterology Organisation Global Guidelines Constipation: a global perspective November 2010 Review team Greger Lindberg (Chairman) Saeed Hamid (Pakistan) Peter Malfertheiner (Germany) Ole Thomsen (Denmark) Luis Bustos Fernandez (Argentina) James Garisch (South Africa) Alan Thomson (Canada) Khean-Lee Goh (Malaysia) Rakesh Tandon (India) Suliman Fedail (Sudan) Benjamin Wong (China) Aamir Khan (Pakistan (...) ) Justus Krabshuis (France) Anton Le Mair (The Netherlands) WGO Global Guideline Constipation 2 © World Gastroenterology Organisation, 2010 Contents 1 Introduction 3 1.1 Cascades—a resource-sensitive approach 3 2 Definition and pathogenesis 3 2.1 Pathogenesis and risk factors 3 2.2 Associated conditions and medications 4 3 Diagnosis 6 3.2 Diagnostic criteria for functional constipation 6 3.2 Patient evaluation 6 3.3 Alarm symptoms 7 3.4 Indications for screening tests 8 3.5 Transit measurement 8 3.6

2010 World Gastroenterology Organisation

187. Constipation in children and young people: diagnosis and management

Constipation in children and young people: diagnosis and management Constipation in children and y Constipation in children and young oung people: diagnosis and management people: diagnosis and management Clinical guideline Published: 26 May 2010 nice.org.uk/guidance/cg99 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view (...) in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Constipation in children and young people: diagnosis and management (CG99) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms

2010 National Institute for Health and Clinical Excellence - Clinical Guidelines

188. Prucalopride for the treatment of chronic constipation in women (TA211)

Prucalopride for the treatment of chronic constipation in women (TA211) Overview | Prucalopride for the treatment of chronic constipation in women | Guidance | NICE Prucalopride for the treatment of chronic constipation in women Technology appraisal guidance [TA211] Published date: 15 December 2010 Share Guidance on prucalopride (Resolor) for treating chronic constipation in women. Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

189. Constipation

Constipation © 2010, Dutch College of General Practitioners www.nhg.org Appendix to H&W, 2010, 53, No. 9, page 484 september 2010 Constipation in adults is diagnosed if there are at least two of the following symptoms: ? defecation frequency = 2 per week; ? increased straining during defecation; ? hard and/or pebble -like defecation; ? feeling of incomple te defecation; ? feeling of anorecta l obstruction/blockage; ? manual manoeuvres to facilitate defecation. Constipation in children (...) to promote defecation; incomplete defecation; dif ficult faecal passage; indications of irritable bowel syndrome). ? Diet (suf ficient fluid intake; suf ficient fibre intake). ? Causal factors and consequences (pain during defecation; rectal blood loss; use of laxatives and medication with constipation as a side ef fect; hypothyroidism, diabetes mellitus, pregnancy , Parkinson's disease, multiple sclerosis). ? General symptoms: increasing abdominal pain and vomiting, discomfort, weight loss. Additional

2010 Dutch College of General Practitioners (NHG)

190. Methylnaltrexone (Relistor) for opioid-induced constipation

Methylnaltrexone (Relistor) for opioid-induced constipation 2010. DAR No 5: Methylnaltrexone (Relistor®) for opioid-induced constipation - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 5: Methylnaltrexone (Relistor®) for opioid-induced constipation DAR No 5: Methylnaltrexone (Relistor®) for opioid-induced constipation Content tools Share it Subcutaneous route instead of suppository or enema in terminal patients The use

2010 Drug and Therapeutics Bulletin of Navarre (Spain)

191. LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial

LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial Speed C, Heaven B, Adamson A, Bond J, Corbett S, Lake AA, May C, Vanoli A, McMeekin P, Moynihan P (...) , Rubin G, Steen IN, McColl E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Speed C, Heaven B, Adamson A, Bond J, Corbett S, Lake AA, May C, Vanoli A, McMeekin P, Moynihan P, Rubin G, Steen IN, McColl E. LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial. Health

2010 Health Technology Assessment (HTA) Database.

192. Prucalopride for the treatment of chronic constipation in women

Prucalopride for the treatment of chronic constipation in women Prucalopride for the treatment of chronic constipation in women Prucalopride for the treatment of chronic constipation in women National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Prucalopride (...) for the treatment of chronic constipation in women. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 211. 2010 Authors' conclusions Prucalopride is recommended as an option for the treatment of chronic constipation only in women for whom treatment with at least two laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and invasive treatment for constipation is being considered

2010 Health Technology Assessment (HTA) Database.

193. The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK

The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK Taylor RR, Guest JF Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to estimate the cost-effectiveness of macrogol 3350, compared with lactulose, for the treatment of chronic constipation in adults. The authors concluded that macrogol 3350 was cost-effective. The methods and the reporting of the results were good

2010 NHS Economic Evaluation Database.

194. New-onset constipation at acute stage after first stroke: incidence, risk factors, and impact on the stroke outcome Full Text available with Trip Pro

New-onset constipation at acute stage after first stroke: incidence, risk factors, and impact on the stroke outcome The prevalence of constipation after stroke varies from 30% to 60%. The incidence of new-onset constipation during the early stage of stroke remains uncertain. The present study was designed to investigate the prevalence of new-onset constipation, its risk factors, and its impact on stroke outcome in patients with their first stroke at acute stage.This is a prospective cohort (...) study of 154 patients admitted with their first stroke. New-onset constipation during the first 4 weeks of stroke was recorded, using the Rome II criteria for constipation. Demographics, characteristics of the stroke, laboratory parameters, and use of medications were evaluated as risk factors for constipation. Death, recurrent stroke, and handicap at 12 weeks were regarded as poor outcome. The impact of constipation on poor outcome was also studied.The cumulative incidence of new-onset constipation

2009 EvidenceUpdates

195. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study Full Text available with Trip Pro

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively impacts quality of life (QoL).A randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of a selective, high-affinity 5-HT(4) receptor agonist (...) , prucalopride, in patients with chronic constipation [or=3 SCBMs/week, averaged over 12 weeks. Other assessments included BM frequency, constipation-related QoL and symptoms and tolerability.Among 641 patients, significantly more patients taking prucalopride 2 or 4 mg (24%) than placebo (12%), achieved

2009 EvidenceUpdates Controlled trial quality: predicted high

196. Methylnaltrexone bromide - Constipation, Opioid-induced

Methylnaltrexone bromide - Constipation, Opioid-induced Common Drug Review CEDAC Meeting – November 19, 2008, CEDAC Reconsideration – January 21, 2009 Page 1 of 2 Notice of CEDAC Final Recommendation – January 28, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION METHYLNALTREXONE (Relistor ™ – Wyeth Canada) Description: Methylnaltrexone is a mu-opioid receptor antagonist approved by Health Canada for the treatment of opioid-induced constipation (...) outcome, was similar in the methylnaltrexone and placebo groups during the second week of the only two week study. Summary of Committee Considerations: The Committee considered a systematic review of two double-blind randomized controlled trials evaluating the effects of methylnaltrexone compared to placebo in palliative care patients taking other laxatives (n=287). The study population included many patients who did not report severe constipation at baseline and whose background regimens were

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

197. The use of naloxone for the treatment of opioid-induced constipation (OIC)

The use of naloxone for the treatment of opioid-induced constipation (OIC) "The use of naloxone for the treatment of opioid-induced constipation (" by Curtis Cole < > > > > > Title Author Date of Graduation 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Rob Rosenow PharmD, OD Second Advisor Annjanette Sommers MS, PAC Rights . Abstract Background: Opioid-induced constipation (OIC) is a major problem that can have a significant (...) impact on a patient’s quality of life (QoL). The use of opioids for both long and short term analgesia has been the standard treatment for many years. All opioids, like oxycodone, can be connected with the development of bowel dysfunction, with constipation being one of the more frequently reported adverse effects. Many of the standard methods and protocols that hospitals use seem to have little effect on this continuing problem. Hypothesis: That the use of oral naloxone Prolonged Release (PR

2009 Pacific University EBM Capstone Project

198. [Methylnaltrexone for opioid-induced constipation in cancer treatment]

[Methylnaltrexone for opioid-induced constipation in cancer treatment] Metylnaltrekson ved forstoppelse i kreftbehandling [Methylnaltrexone for opioid-induced constipation in cancer treatment] Metylnaltrekson ved forstoppelse i kreftbehandling [Methylnaltrexone for opioid-induced constipation in cancer treatment] Movik E, Ringerike T, Linnestad KK, Hofmann, B, Harboe I, Klemp M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Movik E, Ringerike T, Linnestad KK, Hofmann, B, Harboe I, Klemp M. Metylnaltrekson ved forstoppelse i kreftbehandling. [Methylnaltrexone for opioid-induced constipation in cancer treatment] Oslo: Norwegian Knowledge Centre for the Health Services (NOKC). Report from NOKC nr 23 - 2009.. 2009 Authors' conclusions Our review suggests that methylnaltrexone was more effective than placebo in terms of time to laxation

2009 Health Technology Assessment (HTA) Database.

199. Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures Full Text available with Trip Pro

Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment (...) and dietary measures Pijpers MA, Tabbers MM, Benninga MA, Berger MY CRD summary The review found that there was insufficient evidence to show that laxatives were superior to placebo for treating constipation in children and that no one laxative could be recommended over any other. Although the review was limited in some respects, in particular the failure to address statistical heterogeneity, the authors' cautious conclusions appear justified. Authors' objectives To determine the effectiveness

2009 DARE.

200. Biofeedback therapy in fecal incontinence and constipation

Biofeedback therapy in fecal incontinence and constipation Biofeedback therapy in fecal incontinence and constipation Biofeedback therapy in fecal incontinence and constipation Enck P, van der Voort IR, Klosterhalfen S CRD summary The authors concluded that there was evidence of a substantial therapeutic effect of biofeedback therapy for constipation due to pelvic floor dyssynergia, but lack of evidence for biofeedback therapy for incontinence. There were a number of limitations to this review (...) . In particular, the review did not report data specific to pelvic floor dyssynergia, so these conclusions may not be reliable. Authors' objectives To evaluate the efficacy of biofeedback therapy for the treatment of constipation and faecal incontinence. Searching PubMed was searched for studies published in English between 1980 and 2008; search terms were reported. In addition, reference lists in identified articles, reviews and meta-analyses were screened. Study selection Randomised controlled trials (RCTs

2009 DARE.